ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.77
−3.72%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.14
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.11
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -5.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $21
- PT range
- $20 – $22
- Analysts
- 4
2 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.11 | -$0.14 | Miss -25.71% | — |
| May 11, 2026 | -$0.12 | -$0.11 | Beat 4.35% | — |
| Nov 12, 2025 | -$0.11 | -$0.11 | In line | — |
| Aug 12, 2025 | -$0.12 | -$0.12 | In line | — |
| Mar 20, 2025 | -$0.12 | -$0.11 | Beat 8.33% | — |
| Nov 9, 2023 | -$0.21 | -$0.20 | Beat 4.76% | — |
| Aug 10, 2023 | -$0.27 | -$0.21 | Beat 22.22% | — |
| May 15, 2023 | -$0.30 | -$0.22 | Beat 26.67% | — |
| Mar 23, 2023 | -$0.30 | -$0.28 | Beat 6.67% | — |
| Aug 11, 2022 | -$0.34 | -$0.30 | Beat 11.76% | — |
| May 12, 2022 | -$0.30 | -$0.31 | Miss -3.33% | — |
| Mar 24, 2022 | -$0.31 | -$0.26 | Beat 16.13% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026